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Background: Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term
survival. Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with
AML ≥65 years marks the potential for hypomethylating agents in elderly AML. Nevertheless the situation is
dissatisfactory and the quest for novel treatment approaches, including combination epigenetic therapy is actively
ongoing. The given randomized trial should be helpful in investigating the question whether combinations of DAC
with the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and/or all-trans retinoic acid (ATRA), which in vitro
show a very promising synergism, are superior to the DAC monotherapy. The accompanying translational research
project will contribute to find surrogate molecular end points for drug efficacy and better tailor epigenetic therapy.
An additional aim of the study is to investigate the prognostic value of geriatric assessments for elderly AML patients
treated non-intensively.
Methods/Design: DECIDER is a prospective, randomized, observer blind, parallel group, multicenter, Phase II study
with a 2x2 factorial design. The primary endpoint is objective best overall response (complete remission (CR) and
partial remission (PR)). The target population is AML patients aged 60 years or older and unfit for standard induction
chemotherapy. Patients are randomized to one of the four treatment groups: DAC alone or in combination with VPA
or ATRA or with both add-on drugs. One interim safety analysis was planned and carried out with the objective to
stop early one or more of the treatment arms in case of an unacceptable death rate. This analysis showed that in all
treatment arms the critical stopping rule was not reached. No important safety issues were observed. The Data
Monitoring Committee (DMC) recommended continuing the study as planned. The first patient was included in
December 2011. A total of 189 out of 200 planned patients were randomized since then (status 31.12.2014).
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number: DRKS00000733 (registration date 19.04.2011).
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Acute myeloid leukemia (AML) of the older patient
constitutes a major unmet clinical need since the large
majority will not be found eligible for induction chemo-
therapy. Reasons for this decision include host factors
(comorbidities, reduced performance status, functional
limitations due to age), often leading to poor tolerance
of repeated chemotherapy courses, as well as the unfavor-
able biology of this disease in older patients. Among low
dose cytarabine, azacitidine or best supportive care,
the hypomethylating agent (HMA) decitabine (DAC)
represents one of the therapeutic options for these pa-
tients providing effectiveness, good tolerability and
maintenance of quality of life. In this trial, we ask
whether a combination of DAC with the histone deace-
tylase inhibitor VPA and/or ATRA is able to increase
the objective best response rate to DAC alone in AML
of the elderly.
Rationale for combination of DAC und VPA in AML
Since the pioneering discovery by Cameron et al. [1] of a
synergism between demethylation and histone deacety-
lase (HDAC) inhibition in the re-expression of silencing
genes, investigations have been advanced in pre-clinical
and clinical studies using the two DNA methyltransfer-
ase inhibitors available (azacitidine and decitabine) in
combination with different HDAC inhibitors. Research
of the additional effects of HDAC inhibitors appears par-
ticularly important and promising, since both mouse
data [2, 3] and ex vivo results [4] have given clear indica-
tions that a combination of demethylation agents with
HDAC inhibitors may exhibit beneficial effects on the
normal hematopoiesis as well as on active suppression
of the malignant clone. Three clinical studies investi-
gated the combination of DAC and VPA in AML/MDS
patients. In a large Phase II study performed at the MD
Anderson Cancer Center (MDACC) [5], DAC (10 daily
one hour infusions) was given concomitantly with escalat-
ing doses of VPA over 10 days to 54 patients. A response
rate of 22 % was observed (10 CR, 2 CR with incomplete
platelet recovery). Based on the toxicity profile, this com-
bination was judged safe and active. Transient reversal of
aberrant epigenetic marks was noted. In a study coordi-
nated by the Ohio State University [6], 25 patients were
treated with DAC for 10 days, and escalating VPA
doses on days 5–21. A response rate of 44 % was re-
ported (4 CR, 4 CR with incomplete platelet recovery, 3PR). Overall, non-hematologic toxicity was limited,
however with dose-limiting encephalopathy noted in
several patients. Also in that study, epigenetic marks
were studied in conjunction with treatment. Re-
expression of estrogen receptor (ER) was shown to be as-
sociated with the clinical response. ER promoter de-
methylation, global DNA hypomethylation, depletion
of DNA methyltransferase enzyme, and histone hyper-
acetylation were observed. A large randomized trial in-
vestigating clinical response and epigenetic modulation of
DAC with or without VPA has been recently published by
the MDACC [7]. The study could not show a benefit of
the simultaneous addition of VPA to DAC in MDS/
AML patients suggesting that different scheduling re-
gimes have to be explored.Rationale for the combination of DAC and ATRA in AML
An intriguing rationale of the potential sensitization of
non-M3 blasts to the effects of ATRA by pre-treatment
with chemotherapy or azanucleosides has driven import-
ant lines of investigation. Several large clinical studies
have addressed the role of ATRA when given in combin-
ation with high-dose chemotherapy: Schlenk and col-
leagues could show that the addition of ATRA to
induction therapy in AML patients >60 years resulted in
a survival benefit [8]. However, large studies by the Med-
ical Research Council and MDACC did not show an
additional effect of ATRA [9–11], which may be due to
the timing of the dosing and/or different patient popu-
lations [12].
We have begun to address the question of a combin-
ation of DAC +ATRA by implementing a four week
treatment of ATRA in a multicenter study during the
second course of DAC, in patients showing sensitivity to
DAC alone. Comparison of the overall survival of pa-
tients who did or did not receive ATRA during the sec-
ond course did not reveal a superior outcome for
patients who received ATRA [13]. The study showed
feasibility of the combination DAC +ATRA in the clin-
ical setting and comparability of its safety profile to that
of DAC given alone. Furthermore, we could recently
demonstrate that AML cell lines treated in vitro with
DAC (either alone or in combination with ATRA or the
HDAC inhibitor entinostat) showed enhanced in vitro
differentiation in the presence of the retinoid, providing
an additional rationale to combine ATRA with the
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that a controlled setting is needed to investigate this re-
search question accurately.
Rationale for the combination of VPA and ATRA in AML
Preclinical results of several groups have demonstrated
that VPA alters the sensitivity towards ATRA, providing
a strong rationale to advance this approach also clinic-
ally [15, 16]. Several groups combined VPA with ATRA
in the treatment of MDS and AML [16–18] and showed
good tolerability of this combination. In the study of the
MDACC a total of 53 patients with high-risk MDS or re-
fractory/relapsed AML were treated with a three-drug
combination: azacitidine, VPA and ATRA. The overall
response rate was 42 %. In previously untreated older
patients, the response rate was 52 %. The treatment was
shown to be safe and associated with induction of global
DNA hypomethylation and histone acetylation [19].
However, the role of the drug combinations has not been
tested in a rigorous fashion using a randomized design.
This appears important in the context of a study with
DAC, since the available evidence suggests that combi-
nations of this HMA with a second epigenetic drug and
an inducer of differentiation may reveal efficacy that is
superior to the HMA alone.
Thus, in this trial, we ask whether a combination of
DAC with the HDAC VPA or ATRA or with both add-on
drugs is able to increase the objective best response rate to
DAC alone in AML of the elderly. The hypothesis that the
combination is more active than single-agent DAC will be
investigated in a randomized setting.
Methods/Design
Study design and setting
This is a prospective, randomized, observer blind, active
control, parallel group, multicenter, phase II study. The
objective of the trial is the investigation of efficacy and
safety of the histone deacetylase inhibitor (VPA) and
all-trans retinoic acid (ATRA) as add-on to the epigeneti-
cally active drug decitabine (DAC) in older and unfit acute
myeloid leukemia (AML) patients.
The trial has a 2x2 design randomizing the patients to
the following four treatment arms: DAC, DAC + VPA,
DAC +ATRA, DAC + VPA + ATRA. The effect of VPA
will be investigated by comparing the combined treat-
ment arms (DAC + VPA) and (DAC + VPA + ATRA) as
experimental group versus the combined treatment arms
(DAC) and (DAC+ATRA) as control group, and the effect
of ATRA will be investigated by comparing the combined
treatment arms (DAC+ATRA) and (DAC+VPA+ATRA)
as experimental group versus the combined treatment
arms (DAC) and (DAC+VPA) as control group.
Trial sites are located in Aachen, Berlin, Bochum,
Braunschweig, Bremen, Düsseldorf (two sites), Esslingen,Frankfurt, Freiburg, Hagen, Halle, Hamm, Hannover, Jena,
Koblenz, Lahr, Lebach, Leipzig, Lüdenscheid, Marburg,
München, Münster, Offenburg, Ravensburg, Tübingen,
Ulm, and Villingen-Schwenningen.
The study and all participating sites were approved
by the central ethics committee (University of Freiburg,
76/10) and the respective local ethics committees. Pa-
tient’s written consent to participate in this clinical trial
and translational research program was obtained prior
to any study-specific procedures. The identifying num-
ber of the DECIDER trial in ClinicalTrials.gov registry
is NCT00867672 and in German clinical trials registry
DRKS00000733.
Study population
The target population of this trial represents patients older
than 60 years with AML according to WHO (≥20 % blasts
in the peripheral blood or bone marrow) not qualifying
for, or not consenting to, standard remission-induction
chemotherapy or immediate allografting. Key inclusion
criteria are: patient’s written informed consent; 60 years or
older at time of informed consent; patients with primary
or secondary AML according to WHO who are not ex-
pected to benefit from standard remission-induction
chemotherapy; <30.000 leukocytes/μl and performance
status ECOG 0, 1, 2. Key exclusion criteria are: Acute pro-
myelocytic leukemia (APL), AML of FAB subtype M3;
previous remission-induction chemotherapy for MDS or
AML, previous allografting; previous treatment with DAC,
5-azacytidine, VPA or another histone deacetylase inhibi-
tor, or ATRA; “low-dose” chemotherapy (e.g., hydroxy-
urea, cytarabine (Ara-C), melphalan, clofarabine etc.)
within four weeks prior to DAC treatment, except for
cytoreduction of leukocytosis ≥30.000/μl with hydroxyurea
or Ara-C as proscribed by the study protocol; treatment
with tyrosine kinase inhibitors, immunomodulating agents
or other investigational AML treatment within the last
four weeks or in a time period of drug half-life x 5
(whatever is shorter) before the first administration of
DAC; treatment with cytokines within the previous four
weeks. Further exclusion criteria are related to general
medical conditions or contraindications to administra-
tion of investigational products according to Summary
of Product Characteristics.
Study treatment and procedures
Study treatment in the four study arms Fig. 1 is as fol-
lows: (DAC) intravenous decitabine 20 mg/m2 over 1 h,
5 days (total dose 100 mg/m2), repeated every 4 weeks;
(DAC + VPA) intravenous decitabine 20 mg/m2 over 1 h,
5 days (total dose 100 mg/m2), repeated every 4 weeks,
and VPA (p.o.) from day 6 of first cycle continuously
throughout all treatment cycles in a dose to achieve a
VPA serum level between 50 to 110 mg/l; (DAC +
Fig. 1 Trial flow. *If WBC ≥ 30.000/μl: Hydroxyurea (HU) or Ara-C until WBC < 30.000/μl. CR = complete remission; PR = partial remission;
ALE = antileukemic effect; SD = stable disease
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(total dose 100 mg/m2), repeated every 4 weeks and
ATRA (45 mg/m2 p.o.) from day 6 to day 28 of each
treatment cycle; (DAC + VPA +ATRA) intravenous deci-
tabine 20 mg/m2 over 1 h, 5 days (total dose 100 mg/
m2), repeated every 4 weeks and VPA (p.o.) from day 6
continuously throughout all treatment cycles in a dose
to achieve a VPA serum level between 50 to 110 mg/l
and ATRA (45 mg/m2 p.o.) from day 6 to day 28 of each
treatment cycle. Treatment cycles are repeated until re-
lapse/progression, hematopoietic stem-cell transplant-
ation, ongoing cytopenia, other unacceptable toxicity or
patient’s death. Response assessment is performed at
the end of the cycles 2, 4 and 6, and thereafter every
third cycle. Study visits are carried out at least once amonth during the treatment and every three months
after treatment discontinuation until 12 months after
randomization of the last patient.
Study endpoints
The primary endpoint is the objective best overall response,
defined as complete remission (CR) or partial remission
(PR). Patients are counted as objective responders if they
achieve a CR or a PR. All other patients are counted as
non-responders. Secondary endpoints for the evaluation of
efficacy are the following: (1) the overall best response de-
fined as CR, PR, or antileukemic effect (ALE). Patients
are counted as responders if they achieve a CR, PR or
ALE. All other patients are counted as non-responders.
The determination of CR, PR, and ALE will be performed
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sion free survival (PFS) time from randomization until re-
lapse/progression or death. For patients being
progression-free and alive at the end of the study, the PFS
time will be censored at the time of the last evaluation of
bone marrow, (3) overall survival (OS) time from
randomization until death of the patients. For patients be-
ing alive at the end of the study, the OS time will be cen-
sored at the time of the last visit or follow-up contact, (4)
quality of life of the patients using the EORTC QLQ-C30
Quality of Life Questionnaire, (5) number of nights in hos-
pital. Further secondary endpoint for evaluation of the
treatments is safety and toxicity, which are evaluated by
means of adverse events (AEs) occurring from the first ad-
ministration and until 4 weeks after the last administration
of the study treatment, death and laboratory assessments.
Sample size
Sample size calculation is based on the rate of patients
experiencing the primary endpoint objective best overall
response (CR or PR). It is the aim of this phase II study
to come to a decision whether the experimental treat-
ments VPA and ATRA are promising treatment options
being worthy of further investigation in phase III. There-
fore, it is not necessary and desired to come to a defini-
tive and rigorous statistical proof of the efficacy of VPA
and ATRA in this study. Nevertheless, statistical tests on
the effects of VPA, i.e., (DAC +VPA) and (DAC +VPA +
ATRA) vs. (DAC) and (DAC +ATRA), and ATRA, i.e.,
(DAC +ATRA) and (DAC +VPA +ATRA) vs. (DAC) and
(DAC +VPA), will be conducted. Both tests will be per-
formed at a one-sided significance level of 10 %. Based on
the results of our single-arm Phase II study of DAC in
AML (Study 00331, NCT00866073) [22], which has re-
cruited 235 patients in Germany, an objective best overall
response rate (ORR) of about 25 % in treatment arm
(DAC) is assumed. The study should have a power of 80 %
to detect an increase in the ORR, when the ORR after ap-
plication of VPA or ATRA is about 40 %. This corre-
sponds to an odds ratio of 2 between the treatment arms
no VPA vs. VPA and no ATRA vs. ATRA, respectively. It
is further assumed that VPA and ATRA do not show an
antagonistic effect. With these assumptions, 176 patients
have to be included in this study. This was calculated with
formula (3) in Campbell et al., 1995 [23] for the Chi
square-test of the hypothesis that the difference between
the rates is equal to zero, and is adequate also for analysis
with logistic regression [24]. To account for the possibility
of some protocol violations, 200 patients will be random-
ized in total (ratio of 1:1:1:1 to the four treatment arms).
Randomization
Center-stratified block randomization with randomly
varying block size is performed based on computer-generated lists. Block sizes are documented separately
from the study protocol in a document not accessible to
investigators. Randomization is performed centrally in
order to guarantee concealment of treatment allocation.
Blinding of the VPA and ATRA intake is impossible
since serum levels of VPA will be measured, and therefore
placebo control will not be feasible. However, concealment
of randomization will be guaranteed to minimize selection
bias, and reviewers of response will be blinded with regard
to the patient’s treatment arm to minimize assessment
bias.Statistical analysis
The primary efficacy analysis of this clinical trial will
be conducted according to the intention-to-treat
principle. This means that the patients will be ana-
lyzed in the treatment arms to which they were ran-
domized, irrespective of whether they refused or
discontinued the treatment or whether other proto-
col violations are revealed. The analysis of the effects
of the different treatment schedules (VPA vs. no
VPA and ATRA vs. no ATRA) with respect to the
primary endpoint objective best overall response will be
performed with a logistic regression model. The treat-
ment effects will be tested using the Wald test at a
one-sided significance level of 10 %, and as estimates of
the effect sizes the odds ratios will be given with 95 %-
confidence intervals. A multiplicative interaction effect
between VPA and ATRA will be included in the logistic
regression model and its size will be estimated with
95 %-confidence interval. The analysis of the treatment
effects with respect to the secondary endpoints PFS
and OS will be performed with the Cox model. The
analysis of the treatment effects with respect to the sec-
ondary endpoint overall best response (CR, PR and
ALE) will be performed with a logistic regression
model. The PFS rates and the OS rates of the different
treatment arms will be estimated by the Kaplan-Meier
method, and the ORR of the different treatment arms
will be estimated as relative frequencies. For evaluating
QOL, scores will be calculated according to Fayers et al.,
2001 [25]. At the different time points during follow-up
changes in relation to baseline will be calculated. With re-
spect to the secondary endpoints QOL and number of
nights in hospital, the treatment groups will be compared
descriptively.
Safety is analyzed in the safety population includ-
ing all randomized patients who received at least
one dose of study medication, and patients are ana-
lyzed according to the received treatment. AEs are
coded using Medical Dictionary for Regulatory Activ-
ities (MedDRA). The incidence of AEs is calculated
as the number of patients who experienced at least
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total number of patients in the safety population.
Interim analysis
One interim analysis with respect to safety had to be
performed three months after 22 patients have been
randomized in each treatment arm. The objective of
this analysis is to enable early stopping of one or
more of the treatment arms in case of an unaccept-
able death rate. A stopping rule was established
based on the following considerations: an analysis of
the one arm Phase II study of DAC in AML (Study
00331, NCT00866073) showed a three-months death
rate of about 35 % which is commonly regarded as
acceptable. A three-months death rate of 70 % or
higher is regarded as unacceptable and should lead to
an early stop of the treatment arm. The error probability
of early stopping if the three-months death rate is accept-
able in reality (<35 %) was set as ≤5 %, and the error prob-
ability of continuing a treatment arm if the three-months
death rate is unacceptable in reality (>70 %) was set as
≤5 %.
Central hematopathology
A systematic central hematopathology review of serial
bone marrow aspirates, bone marrow biopsies and
matching peripheral blood smears of patients on the
study is being conducted at the Institute of Clinical
Pathology, University of Freiburg. The review is per-
formed by a very experienced hematopathologist who is
blinded to the treatment arm to which each patient is
randomized. Written reports (patients are pseudony-
mized) are then sent to the local principle investigators
at the respective study centers.
The review procedure includes a differential count of
peripheral blood (200 cells) and bone marrow smears
(500 cells) as well as histological blast quantification, in-
cluding enumeration after immunohistochemistry for
CD34 and CD117 on bone marrow biopsies. It serves
to support the study physicians’ treatment decisions,
particularly in the setting of patient relapse/progressive
disease. Beyond the quality control for central response
evaluation, and post hoc support of the cytology results
of the local centers, the central hematopathology re-
view process allows for additional, exploratory studies
such as those of bone marrow fibrosis, quantification of
dysplasia, enumeration of megakaryocytes, and quanti-
fication of bone marrow cellularity. These measure-
ments, conducted in a highly standardized fashion,
would not be feasible by decentralized diagnostic pro-
cedures in a multicenter trial.
The compliance of the trial sites with the central
hematopathology review in sending samples is >90 %. A
repository of bone marrow and blood samples will bevery valuable also for future adjunct studies involving
immunohistochemistry, FISH and molecular techniques.
Central cytogenetics and molecular diagnostics
Cytogenetic and molecular genetic studies are being
performed in the central reference laboratory of the
German–Austrian Acute Myeloid Leukemia Study Group
(AMLSG), at the University of Ulm. For conventional cyto-
genetic analysis, standard techniques are used and chromo-
somal abnormalities are described according to the
International System for Cytogenetic Nomenclature [26].
The adherence in sending samples to the central laboratory
is >95 % (in DECIDER sites which are members of the
AMLSG) and informative karyotypes are obtained in >90 %
of the patients. In addition, diagnostic samples from all pa-
tients are screened for the recurring gene fusions PML/
RARA, CBFB/MYH11, and RUNX1/RUNX1T1 as well as
for the presence of mutations in the genes encoding FLT3
(i.e., the ITD and TKD mutations at codons D835 and
I836) CEBPA and NPM1. In analogy, success rate of
molecular genetic analysis is >95 %; study centers are
being informed on molecular screening results within a
time window of 48 h.
Central pharmacy
The central pharmacy of the Medical Center – University
of Freiburg has a very long-standing experience in the
preparation and handling of DAC. Senior staff mem-
bers of the pharmacy have been involved already in the
early European phase II DAC studies since 1996.
Therefore a wealth of knowledge exists in handling of
the solubilized solution until infusion of this notori-
ously unstable nucleoside. From the very beginning of
the study (before the DAC marketing authorization in
the EU) the central pharmacy supported and consulted
study sites on preparation of decitabine. Furthermore,
the central pharmacy has the task of distributing the
oral study drug VPA to the different German study
sites in accordance with German laws.
Serial assessment of patient fitness and psychological
state
As in the predecessor phase II trial in elderly, non-fit AML
patients receiving DAC (study 00331, NCT00866073), sys-
tematic functional assessment of the patients is being con-
ducted prior to randomization and at several defined time
points during and after the study treatment [27]. It is an
additional aim of the study to investigate the prognostic
value of geriatric assessments for elderly AML patients
treated non-intensively. This includes determination of the
activities of daily living (ADL) by application of the Barthel
index, assessment of quality of life by the EORTC-C30
questionnaire, application of the Hospital and Anxiety De-
pression Scale (HADS), and determination of psychological
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addition, the performance status (Eastern cooperative on-
cology group performance status, ECOG) of the patient is
captured before and at defined time points during the
treatment. Comorbidities are scored prior to treatment
using the Hematopoietic Cell Transplantation-Comorbidity
Index (HCT-CI). The compliance with this functional
assessment is >90 %.
Translational research program
The study provides the opportunity to address not only
baseline genetic and epigenetic characteristics of the pa-
tient blasts with relation to the clinical response, but also
mRNA expression and epigenetic changes induced by the
treatment. Bone marrow and peripheral blood cells are
procured prior to treatment within the standard diagnostic
workup, and in patients consenting to serial sampling, also
at defined, early and late time points during the treatment.
Furthermore serum is being collected and cryopreserved
for future studies on miRNA expression changes with this
epigenetic treatment. Serial anticoagulated blood sample
allow for cell sorting for blasts vs. T-cells as well as isola-
tion of granulocytes (provided patients have sufficient cell
numbers at the different time points).
Quality assurance system
During the clinical trial, quality control is ensured
through monitoring, auditing and supervision by the au-
thorities, if applicable. The Clinical Trials Unit of the
Medical Center - University of Freiburg, Germany, is re-
sponsible for project coordination, statistical planning
and analysis, data management, clinical monitoring and
pharmacovigilance. An independent DMC consisting of
three hemato-oncologists and one statistician was estab-
lished. It is the role of the DMC to monitor and supervise
the progress of the trial (including safety data and adher-
ence to the protocol) and to advise whether to continue,
modify or stop the trial. Composition and responsibilities
of the DMC, structure and content of its meetings, and its
relationship to other key study team members are laid
down in a separate DMC charter. The DMC members are
continuously informed about study progress and safety
data. The DMC gave recommendations on study conduct
after the review of the extensive report about the interim
analysis including data on patient recruitment, baseline
characteristics, eligibility violations, treatment compliance,
compliance with planned visits, completeness of follow-
up, and safety separately for the different treatment arms.
Study status
Since the start of recruitment in December 2011, a total
of 189 patients were randomized in the study until
31.12.2014. The interim analysis was conducted in May
2014 by the Clinical Trials Unit, and the confidentialreport was made available only to the coordinating in-
vestigator, medical coordinator, and to the DMC. The in-
terim analysis showed that in all four treatment arms the
critical stopping rule concerning death within three
months after randomization was not reached. Further-
more, no important safety issues have been observed
that would alter the assumed benefit-risk profile. The
DMC statement released in July 2014 recommended
continuing the study as planned, as all DMC members
unanimously agreed that at the moment there are no
ethical or other concerns on further conduct of the trial.
Discussion
Treatment options for elderly AML patients are very lim-
ited because they are less capable of tolerating intensive
cytotoxic induction and post-remission chemotherapy.
The add-on of VPA and/or ATRA - drugs which are
widely used in hematology and have well controllable side
effects - to HMA has been shown to be safe in smaller
studies and to act in synergy in vitro. The aim of our trial
is to investigate the potential benefit of addition of VPA
or/and ATRA to DAC with regard to disease control and
overall survival in a randomized setting. As recommended
by the DMC, after examination of the patients’ data in
frame of the interim safety analysis, the study will be con-
tinued as initially planned. DECIDER is the clinical trial
investigating the potential benefit of adding VPA or/and
ATRA to DAC in view of disease control, overall survival,
safety and quality of life in elderly AML patients in a ran-
domized setting.
Abbreviations
AE: Adverse event; ALE: Antileukemic effect; AML: Acute myeloid leukemia;
ATRA: All-trans retinoic acid; CR: Complete remission; DAC: Decitabine;
DMC: Data monitoring committee; EORTC: European organization for
research and treatment of cancer; HDAC: Histone deacetylase;
HMA: Hypomethylating agent; MDS: Myelodysplastic syndrome;
ORR: Objective best overall response rate; OS: Overall survival; p.o.: per os;
PFS: Progression-free survival; PR: Partial remission; QOL: Quality of life;
SD: Stable disease; VPA: Valproic acid; Vs.: versus; WBC: White blood cell
count; WHO: World health organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OG coordinates the trial and is responsible for pharmacovigilance. CS
designed the trial and is responsible for statistical planning, randomization,
and statistical analysis. KD is responsible for central cytogenetics and
molecular diagnostics. BH is medical coordinator and deputy of the
coordinating investigator. BL is responsible for central pharmacy. AMM is
responsible for central hematopathology. MM is a member of the clinical
study group. CC coordinates the trial. ML, coordinating investigator,
designed the study and conducts it. All authors contributed to the writing
of the manuscript and read and approved the final version.
Acknowledgements
The DECIDER trial is funded by the Federal Ministry of Education and
Research (BMBF). The study medication was kindly provided by Janssen
Pharmaceutical (DAC) and Ratiopharm/Teva (VPA). ML receives research
support from the German Research Foundation (DFG: SPP 1463, CRC 992).
We gratefully acknowledge the AMLSG study group for technical assistance.
Grishina et al. BMC Cancer  (2015) 15:430 Page 8 of 8We thank the DMC members (Prof. Dr. Thomas Büchner, Prof. Hervé
Dombret, Prof. Dr. Pierre Wijermans and Axel Benner) for their advisory
opinion.
Author details
1Clinical Trials Unit, Medical Center – University of Freiburg, Elsaesser Str. 2,
79110 Freiburg, Germany. 2Department of Internal Medicine III, University
Hospital of Ulm, Albert_Einstein-Allee 23, 89081 Ulm, Germany. 3Department
of Medicine, Division Hematology/Oncology/Stem-Cell Transplantation,
Medical Center – University of Freiburg, Hugstetter Str. 55, 79106 Freiburg,
Germany. 4Pharmacy, Medical Center – University of Freiburg, Hugstetter Str.
55, 79106 Freiburg, Germany. 5Department of Pathology, Institute of Clinical
Pathology, Medical Center – University of Freiburg, Ludwig-Aschoff-Haus,
Breisacher Str. 115a, 79106 Freiburg, Germany.
Received: 20 January 2015 Accepted: 13 May 2015References
1. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of
demethylation and histone deacetylase inhibition in the re-expression of
genes silenced in cancer. Nat Genet. 1999;21:103–7.
2. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y,
et al. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine
and trichostatin A. Blood. 2004;103:4102–10.
3. Araki H, Mahmud N, Milhem M, Nunez R, Xu M, Beam CA, et al.
Expansion of human umbilical cord blood SCID-repopulating cells
using chromatin-modifying agents. Exp Hematol. 2006;34:140–9.
4. Bug G, Gül H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic
Acid Stimulates Proliferation and Self-renewal of Hematopoietic Stem Cells.
Cancer Res. 2005;65:2537–41.
5. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G,
Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′-
deoxycytidine with valproic acid in patients with leukemia. Blood.
2006;108:3271–9.
6. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study
of decitabine alone or in combination with valproic acid in acute myeloid
leukemia. J Clin Oncol. 2007;25:3884–91.
7. Issa J-P, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, et al.
Results of phase 2 randomized study of low-dose decitabine with or
without valproic acid in patients with myelodysplastic syndrome and
acute myelogenous leukemia. Cancer 2015, 121:556–561.
8. Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F,
et al. Phase III study of all-trans retinoic acid in previously untreated patients
61 years or older with acute myeloid leukemia. Leukemia. 2004;18:1798–803.
9. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al.
Randomized phase II study of fludarabine + cytosine arabinoside +
idarubicin +/− all-trans retinoic acid +/− granulocyte colony-stimulating
factor in poor prognosis newly diagnosed acute myeloid leukemia and
myelodysplastic syndrome. Blood. 1999;93:2478–84.
10. Burnett AK, Milligan D, Hills RK, Goldstone AH, Prentice AG, Wheatley K,
et al. Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute
Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials. ASH
Annu Meet Abstr. 2004;104:1794.
11. Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK, NCRI
Haematological Oncology Clinical Studies Group. Fludarabine and
cytosine are less effective than standard ADE chemotherapy in high-
risk acute
myeloid leukemia, and addition of G-CSF and ATRA are not beneficial:
results of the MRC AML-HR randomized trial. Blood. 2006;107:4614–22.
12. Estey E. Clinical trials in AML of the elderly: should we change our
methodology? Leukemia. 2004;18:1772–4.
13. Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A
multicenter phase II trial of decitabine as first-line treatment for older patients
with acute myeloid leukemia judged unfit for induction chemotherapy.
Haematologica. 2012;97:393–401.
14. Blagitko-Dorfs N, Jiang Y, Duque-Afonso J, Hiller J, Yalcin A, Greve G, et al.
Epigenetic priming of AML blasts for all-trans retinoic acid-induced
differentiation by the HDAC class-I selective inhibitor entinostat. PLoS One.
2013;8:e75258.15. Trus MR, Yang L, Suarez SF, Bordeleau L, Jurisica I, Minden MD. The histone
deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic
acid in acute myeloblastic leukemia cells. Leukemia. 2005;19:1161–8.
16. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, et al.
Sequential valproic acid/all-trans retinoic acid treatment reprograms
differentiation in refractory and high-risk acute myeloid leukemia. Cancer
Res. 2006;66:8903–11.
17. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, et al. Results
of a phase 2 study of valproic acid alone or in combination with all-trans
retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or
refractory acute myeloid leukemia. Ann Hematol. 2005;84 Suppl 1:61–6.
18. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical
trial of valproic acid and all-trans retinoic acid in patients with poor-risk
acute myeloid leukemia. Cancer. 2005;104:2717–25.
19. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and
clinical activity of the combination of 5-azacytidine, valproic acid, and
all-trans retinoic acid in acute myeloid leukemia and myelodysplastic
syndrome. Blood. 2007;110:2302–8.
20. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al.
Revised recommendations of the International Working Group for
Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and
Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin
Oncol. 2003;21:4642–9.
21. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al.
Diagnosis and management of acute myeloid leukemia in adults:
recommendations from an international expert panel, on behalf of the
European LeukemiaNet. Blood. 2010;115:453–74.
22. Lubbert M, Ruter B, Claus R, Schmid M, Germing U, Eimermacher H, et al.
Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in
All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331
Multicenter Phase II Study. ASH Annu Meet Abstr. 2007;110:300.
23. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary,
ordered categorical, and continuous outcomes in two group comparisons.
BMJ. 1995;311:1145–8.
24. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation
for linear and logistic regression. Stat Med. 1998;17:1623–34.
25. Fayers PM, Aaronson NK, Bjordal K, Grønvold M, Curran D, Bottomley A.
EORTC QLQ-C30 Scoring Manual. European Organisation for Research and
Treatment of Cancer Brussels; 2001.
26. Mitelman F. An International System for Human Cytogenetic Nomenclature
(1995): Recommendations of the International Standing Committee on
Human Cytogenetic Nomenclature. Memphis, Tennessee, USA: Karger
Medical and Scientific Publishers; 1994.
27. Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de Figuerido M,
et al. Parameters detected by geriatric and quality of life assessment in 195
older patients with myelodysplastic syndromes and acute myeloid leukemia
are highly predictive for outcome. Haematologica. 2013;98:208–16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
